Allurion Technologies (ALUR) announced a new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry. The company signed a term sheet with a strategic partner for ex-US distribution and R&D, including a potential GLP-1 drug-eluting balloon. Allurion also submitted a protocol for a clinical trial on its program combined with a low-dose GLP-1 and reported its PMA application for the Allurion Balloon was accepted by the FDA.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR: